Ma, Wenjuan
Wang, Yanling
Zhang, Rongxin
Yang, Fan
Zhang, Duo http://orcid.org/0000-0003-3215-2466
Huang, Menggui
Zhang, Lin http://orcid.org/0000-0003-1998-0611
Dorsey, Jay F.
Binder, Zev A.
O’Rourke, Donald M.
Fraietta, Joseph A.
Gong, Yanqing
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS094533, R01NS106108)
American Association for Cancer Research (Judah Folkman Award)
Penn | Perelman School of Medicine, University of Pennsylvania (RadOnc-TCE Award, Academic Development Fund, Abramson Cancer Center GBM-TCE Award, Abramson Cancer Center GBM-TCE Award)
Article History
Received: 13 February 2020
Accepted: 20 October 2020
First Online: 30 November 2020
Competing interests
: Y.F. is an inventor on a patent application covering the use of PAK4 inhibitors for vessel normalization therapy. L.Z. received research funding from AstraZeneca, Bristol-Myers Squibb/Celgene and Prelude Therapeutics.